<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02726698</url>
  </required_header>
  <id_info>
    <org_study_id>NL53561.042.16</org_study_id>
    <nct_id>NCT02726698</nct_id>
  </id_info>
  <brief_title>Reappraisal of Atrial Fibrillation: Interaction Between HyperCoagulability, Electrical Remodeling, and Vascular Destabilisation in the Progression of Atrial Fibrillation</brief_title>
  <acronym>RACE V</acronym>
  <official_title>Reappraisal of Atrial Fibrillation: Interaction Between HyperCoagulability, Electrical Remodeling, and Vascular Destabilisation in the Progression of Atrial Fibrillation - An Observational Exploratory Study on Pathophysiological Mechanisms of AF Progression and on the Role of LinQ/CareLink Guided Patient Tailored Therapy in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to study clinical factors and (blood) biomarkers related to&#xD;
      progression of Atrial Fibrillation (AF) in patients diagnosed with self-terminating AF with&#xD;
      special reference to hypercoagulability. All patients will be continuously monitored for&#xD;
      their atrial rhythm to assess AF progression, either through an implantable loop recorder&#xD;
      (Reveal LinQ) or via the atrial lead of a cardiac implantable electronic device (CIED), both&#xD;
      in combination with the CareLink home monitoring system. Remote monitoring and interrogation&#xD;
      will be installed and used on a daily basis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of AF burden</measure>
    <time_frame>2.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac and Cerebrovascular Events</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in therapy due to continuous rhythm monitoring with the LinQ/Carelink system</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with paroxysmal (self-terminating) AF in the cardiology outpatient department,&#xD;
        first (heart) aid and pacemaker clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  New onset or history of paroxysmal, self-terminating AF documented as:&#xD;
&#xD;
               -  AF on ECG or Holter-recording or loop recorder&#xD;
&#xD;
               -  Subclinical AF detected in implantable cardiac devices (atrial read &gt; 190 beats&#xD;
                  per minute, lasting &gt; 6 minutes).&#xD;
&#xD;
          -  Prior history of self-terminating AF is allowed;&#xD;
&#xD;
          -  Able and willing to sign informed consent for the registry;&#xD;
&#xD;
          -  Able and willing to undergo implantation of an implantable loop recorder (in patients&#xD;
             without a CIED);&#xD;
&#xD;
          -  In patients already on oral anticoagulation drugs, the following inclusion criteria&#xD;
             need to be met (to allow for safe temporary interruption of anti-thrombotic treatment&#xD;
             for coagulation phenotyping):&#xD;
&#xD;
               -  CHA2DS2-VASc score ≤5 (history of Congestive heart failure, Hypertension, Age ≥&#xD;
                  75 years (doubled), Diabetes mellitus,Stroke/transient ischemic attack (doubled),&#xD;
                  Vascular disease, Age 65-75 years, female Sex);&#xD;
&#xD;
               -  No other indication for oral anticoagulation (e.g. mechanical valve prosthesis);&#xD;
&#xD;
               -  Patient is willing to temporarily stop oral anticoagulation drugs (OAC).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-self-terminating, persistent AF;&#xD;
&#xD;
          -  Deemed unsuitable or not willing to undergo implantation of loop recorder (in patients&#xD;
             without a CIED);&#xD;
&#xD;
          -  Refusing to temporarily stop OAC for coagulation phenotyping (in patients already on&#xD;
             OAC before inclusion in this study);&#xD;
&#xD;
          -  On waiting list for pulmonary vein isolation or expected to be placed on waiting list&#xD;
             within one year;&#xD;
&#xD;
          -  Expected to start with amiodarone;&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Life expectancy of less than 2.5 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry JGM Crijns, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle C van Gelder, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam University Medical Center - AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam University Medical Center - VU</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini Hospital</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ommelander Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurentius Hospital</name>
      <address>
        <city>Roermond</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>March 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2016</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>I.C. Van Gelder</investigator_full_name>
    <investigator_title>Prof.dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thrombophilia</mesh_term>
    <mesh_term>Atrial Remodeling</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

